Patient-Centric Design in SUNRISE-PD Trial
In a notable presentation at the Advanced Therapeutics in Movement & Related Disorders Congress, BioVie Inc. (NASDAQ: BIVI) showcased its commitment to innovative and patient-centric approaches in clinical trial design. The SUNRISE-PD Phase 2 trial, focusing on bezisterim (NE3107), emphasizes accessibility for patients suffering from Parkinson’s disease (PD), particularly those facing obstacles to conventional trial participation.
Breaking Barriers for Parkinson’s Disease Patients
Parkinson's disease often presents numerous challenges in accessing specialized care. This can include delayed diagnoses, limited mobility, and geographical limitations that hinder participation in clinical trials. The SUNRISE-PD trial aims to alleviate these challenges by incorporating a hybrid, decentralized design, allowing participants to conduct visits either from the comfort of their homes or in clinical settings. This flexibility is crucial for improving access and encouraging broader participation in PD research.
Innovative Therapeutic Approaches
Cuong Do, President and CEO of BioVie, commented on the significance of the SUNRISE-PD trial, stating it represents a pioneering approach in clinical trial design by meeting patients where they are. This model combines the innovative therapeutic potential of bezisterim with a decentralized structure, creating an inclusive environment that encourages participant engagement while maintaining scientific integrity.
Engagement and Support for Patients
The trial targets individuals aged 41 to 80 who have been diagnosed with early-stage PD within the last four years and have not yet begun treatment with standard medications like carbidopa/levodopa. Through collaborations with esteemed organizations, BioVie is actively enhancing awareness and outreach across the U.S., facilitating patient enrollment in this groundbreaking study.
Utilizing Technology to Enhance Trials
SUNRISE-PD employs a flexible design that includes in-home visits conducted by study nurses under the supervision of neurologists, utilizing video conferencing for oversight. Additionally, the assessments of motor symptoms are performed remotely using a modified version of the MDS-UPDRS Part III scale evaluated by a centralized committee. This comprehensive approach ensures the integrity of data collection while prioritizing participant convenience.
Bezisterim: A Novel Treatment Option
Bezisterim is an orally available compound designed to cross the blood-brain barrier, targeting inflammation and insulin sensitivity, with previous trials indicating notable improvements in both motor and non-motor symptoms of PD. This medication aims to address the underlying biological processes contributing to the progression of Parkinson's disease, offering a potential method to modify its long-term impact.
Details of the SUNRISE-PD Presentation
The upcoming presentation at the Congress will provide detailed insights into the SUNRISE-PD study. Here are the specifics:
- Title: SUNRISE-PD: An Ongoing, Hybrid, Decentralized Phase 2 Study of Bezisterim in Early Parkinson’s Disease
- Poster Session: 11:30 am to 12:30 pm, Friday
- Authors: A team of leading researchers and experts
- Poster Position: P 49
- Display Duration: From 7:00 am Friday through 2:00 pm Sunday
Understanding Parkinson’s Disease
Parkinson’s disease is a progressive disorder that significantly impacts movement. It stems from the degeneration of dopamine-producing neurons, leading to core symptoms such as tremors, rigidity, and bradykinesia. Beyond motor symptoms, patients often experience non-motor challenges, including cognitive impairments and mood disorders, which can severely affect daily life.
Exploring the Role of Bezisterim
Research is increasingly uncovering the influence of chronic inflammation and insulin resistance on the development of Parkinson’s disease. Bezisterim's multifaceted mode of action positions it as a promising candidate for addressing these factors effectively. The existing data from past trials underscores its potential for enhancing the quality of life among patients experiencing both motor and non-motor symptoms.
About BioVie Inc.
BioVie Inc., under the stock ticker NASDAQ: BIVI, focuses on developing cutting-edge therapies for neurodegenerative disorders such as Alzheimer's disease, Parkinson’s disease, and long COVID. With their innovative compound, bezisterim, the company is on the forefront of research aimed at tackling the challenges posed by these debilitating conditions while exploring avenues for new treatments.
Frequently Asked Questions
What is the SUNRISE-PD trial?
The SUNRISE-PD trial is a Phase 2 clinical trial evaluating the effects of bezisterim in individuals with early-stage Parkinson’s disease, designed to enhance accessibility and patient participation.
How does bezisterim work?
Bezisterim is an anti-inflammatory, insulin-sensitizing compound that aims to improve both motor and non-motor symptoms in individuals with Parkinson’s disease.
What are the eligibility criteria for the SUNRISE-PD trial?
Participants must be between 41 and 80 years old, diagnosed with early-stage Parkinson's in the last four years, and not yet on treatment with standard therapies.
Where can I find more information about the SUNRISE-PD trial?
For additional information, including details on participation, visit www.SUNRISEPD.com.
Who is leading BioVie Inc.?
BioVie is led by Cuong Do, the President and CEO, who emphasizes patient accessibility in clinical trial designs.
